

3-year contract extension secured with the Cleveland Clinic

11 March 2025

Highlights

- 3-year contract extension secured with the Cleveland Clinic for functional lung imaging software
 - At a minimum of A\$227k over 3 years, this agreement continues trend of growing revenue per site
 - 4DMedical is well positioned to further expand its presence at this prestigious facility
-

Melbourne, Australia, 11 March 2025: Respiratory imaging technology company 4DMedical Limited (ASX:4DX, “4DMedical”, or the “Company”) today announces the renewal and extension of the contract for its pulmonary function Software-as-a-Service analysis with the Cleveland Clinic, a world-renowned academic medical centre and research institution.

4DMedical secures 3-year contract renewal for functional lung imaging

The Cleveland Clinic is an academic medical centre (AMC) globally recognised for its cutting-edge research and excellence in clinical practice. Cleveland consistently ranks in the top 3 hospitals in the U.S. and in the top 10 for pulmonology. The main campus in Cleveland Ohio is a 1,000 bed multispecialty clinical and research facility that spans 170 acres.

AMCs play a significant role in the U.S. healthcare system by integrating a blend of research, education, clinical expertise, and superior resources, meaning that AMCs are influential across the broader U.S. healthcare system, making them important sites for companies like 4DMedical.

The renewed agreement for functional lung imaging extends over a 3-year term, with a minimum contract value of A\$227,000, and layers on top of an existing multi-year agreement for our pulmonary structure products. This 3-year commercial contract is a significant achievement for 4DMedical, and continues the Company’s recent growth in revenue per site.

4DMedical’s SaaS platform provides advanced imaging analysis, delivering unparalleled insights into respiratory function. This extension ensures the Cleveland Clinic can continue leveraging 4DMedical’s innovative technology to advance respiratory health.

4DMedical MD/CEO and Founder Andreas Fouras said:

We are delighted to extend our collaboration with this prestigious academic medical centre and research institution. This renewal strengthens our position as a leading provider of cutting-edge imaging solutions. Their continued trust in our technology underscores the value 4DMedical provides in the field of respiratory health. We have numerous opportunities to expand our existing presence at the Cleveland Clinic, with considerable interest shown at recent congresses in our current and future portfolio, including CT:VQ™. I have personally been involved in several of the discussions with these leading doctors and can feel their enthusiasm for how our solutions will benefit their clinical care and workflow.

–ENDS–

Authorised by the 4DMedical Board of Directors.

Melbourne

Level 7 Melbourne Connect
700 Swanston Street
Carlton VIC 3053
Tel: +61 (3) 9545 5940

Los Angeles

21255 Burbank Boulevard
Suite 120
Woodland Hills CA 91367
Tel: +1 (818) 403-8490

4DMedical Limited
ABN: 31 161 684 831
Email: info@4DMedical.com
www.4DMedical.com



Contacts

Corporate

Chief Financial Officer

Simon Glover

sglover@4dmedical.com

Administration

Company Secretary

Naomi Lawrie

companysecretary@4dmedical.com

Media Enquiries

4Dmedia@4dmedical.com

About 4DMedical

4DMedical Limited (ASX:4DX) is a cutting-edge global medical technology company revolutionizing respiratory care. By harnessing advanced imaging and AI-powered solutions, 4DMedical delivers unprecedented insights into lung function, enabling earlier and more precise diagnoses of respiratory diseases.

At the heart of 4DMedical's innovation is its patented XV Technology®, a groundbreaking platform that dynamically quantifies ventilation throughout the lungs as patients breathe. This technology underpins the company's FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®) and its CT LVAS™, empowering physicians to detect and monitor regional airflow abnormalities with unparalleled sensitivity.

4DMedical's solutions integrate seamlessly into existing hospital infrastructure via its Software as a Service (SaaS) model, transforming routine imaging into powerful diagnostic tools.

In December 2023, 4DMedical expanded its leadership in medical imaging with the acquisition of **Imbio**, a pioneer in artificial intelligence solutions for chronic lung and cardiothoracic diseases. Imbio's AI-driven platforms enhance physician productivity, improve diagnostic precision, and support personalized care, aligning seamlessly with 4DMedical's mission to redefine respiratory healthcare.

To learn more, please visit www.4dmedical.com